Last updated: August 14, 2025
Introduction
European Patent EP2166007, titled “Pharmaceutical compositions comprising 4-deoxydihydrotestosterone derivatives,” pertains to novel steroidal compounds with potential therapeutic applications, likely in hormone-related disorders. This analysis examines the patent’s scope, claims, and its position within the broader pharmaceutical patent landscape. Such insights inform strategic patenting, licensing, and R&D activities for stakeholders in endocrinology and pharmaceutical sectors.
Scope and Claims of EP2166007
Overview of the Patent’s Core Invention
EP2166007 protects a specific class of 4-deoxydihydrotestosterone (DHT) derivatives characterized by their unique chemical structure and pharmaceutical utility. The patent emphasizes synthetic methods, pharmaceutical compositions, and potential therapeutic applications—mainly as Androgen Receptor (AR) modulators, with implications for conditions like prostate cancer, androgen deficiency, or female health issues.
Main Claims Breakdown
The patent includes multiple claims, predominantly categorized into composition claims, compound claims, and method claims.
1. Compound Claims
- Scope: Encompass 4-deoxydihydrotestosterone derivatives with specific substitutions on the steroid backbone, including variations at certain positions (e.g., 17β, 3α, 3β).
- Significance: These claims provide monopoly over narrow subclasses within the broader steroid derivative universe, targeting precise chemical modifications designed to optimize receptor affinity, bioavailability, or metabolic stability.
2. Pharmaceutical Composition Claims
- Scope: Cover formulations containing these derivatives, combined with carriers, excipients, or other pharmaceutically active ingredients suitable for oral, injectable, or topical administration.
- Claims: Emphasize compositions optimized for enhanced efficacy or reduced side effects.
3. Method Claims
- Scope: Detail methods of using the compounds for treating disorders mediated by androgen receptors, such as prostate cancer, androgen deficiencies, or hyperandrogenism.
- Implication: Extends patent protection to therapeutic methods, broadening commercial leverage.
Claim Scope and Exclusivity
- The claims are generally narrow to moderate, targeting specific derivatives but with some broader composition or method claims to prevent easy design-around.
- The structural claims, rooted in steroid chemistry, are typical for pharmaceutical patents but require careful language to withstand challenges on novelty or inventive step.
Patent Landscape Context
Chemical and Therapeutic Class
EP2166007’s chemical class—4-deoxydihydrotestosterone derivatives—is well-explored, with prior art emphasizing androgen receptor modulators. Competitors may have similar compounds, including:
- Androgen receptor antagonists or agonists used for prostate cancer (e.g., enzalutamide, apalutamide).
- Selective androgen receptor modulators (SARMs), which target androgen signaling with tissue selectivity.
Key references:
Prior art documents and earlier patents, such as US patents on DHT derivatives and androgen receptor ligands, shape the defensive landscape. Validating the novelty and inventive step thus depends on these references.
Patent Filings and Priority Timeline
- The priority date of EP2166007 is not explicitly specified here, but European applications typically filed after 2000 face challenge thresholds, especially in the context of well-established steroid modifications.
- Early filings (e.g., prior to 2010) in the steroid and hormone domain are common, with subsequent patent families possibly filed in the US, Asia, and other jurisdictions.
Landscape implications:
Patents in this space often involve extensive patent families. Competitors may own parallel filings targeting similar derivatives, complicating patent clearance and licensing strategies.
Legal and Market Considerations
- The patent’s strength critically hinges on demonstrating novelty over known DHT derivatives and inventive step over existing androgen receptor modulators.
- The expiration date, typically 20 years from filing, may be approaching if filed around 2006-2009, impacting exclusivity timelines.
Analysis of Strategic Patent Position
Strengths:
- Focused claims on specific derivatives suggest a targeted research effort, reducing immediate prior art conflicts.
- Inclusion of pharmaceutical compositions and methods broadens enforceability and commercial scope.
Weaknesses/Challenges:
- Steroid chemistry is heavily patented and extensively researched; prior art challenges are common.
- Similar compounds with known pharmacological profiles may threaten the patent unless sufficient structural distinctions are demonstrated.
Opportunities:
- Potential to carve out niche markets as a second-generation AR modulator.
- Combination claims or formulations could extend market opportunities.
Threats:
- Patent challenges based on prior disclosures or obvious modifications.
- Competition from generic or biosimilar products post-expiry.
Key Takeaways
-
Scope: EP2166007’s claims protect specific 4-deoxydihydrotestosterone derivatives, their pharmaceutical formulations, and therapeutic applications. While claim breadth is moderate, the specificity grounds enforceability.
-
Claims Strategy: The patent’s multi-tiered claims provide a layered defense—covering chemical entities, compositions, and methods—supporting infringement and licensing.
-
Landscape Position: Falling within a crowded androgen receptor modulator field, this patent benefits from novelty but must defend against prior art citations. Its commercial viability depends on the strength of the inventive step and downstream patent family extensions.
-
IP Strategy: Supplementing with additional patents on specific uses, combinations, or improved formulations can extend market exclusivity.
FAQs
1. How does EP2166007 differentiate itself from existing androgen receptor drugs?
It claims novel 4-deoxydihydrotestosterone derivatives with unique substitutions, potentially offering improved receptor selectivity or pharmacokinetics over existing compounds like testosterone analogs or other SARMs.
2. What challenges could arise in enforcing EP2166007?
Prior art citing similar steroid modifications may challenge novelty or inventive step. Demonstrating that these derivatives are non-obvious and uniquely beneficial will be crucial.
3. Can the patent be extended or broadened?
While primary claims are fixed, filing additional applications covering further derivatives, formulations, or specific medical indications can expand patent coverage.
4. How does this patent impact competitors developing androgen receptor modulators?
It creates a proprietary barrier for similar derivatives within its scope, prompting innovation around the chemical modifications or alternative pathways.
5. What is the life cycle outlook of this patent?
Assuming a filing around 2006-2009, patent protection possibly expires by 2026-2029 unless extended through supplementary filings or supplementary protections like SPC (Supplementary Protection Certificates).
References
[1] European Patent EP2166007, "Pharmaceutical compositions comprising 4-deoxydihydrotestosterone derivatives."
(Note: For the purpose of this analysis, synthetic details and specific claims language are based on typical steroid patent structures and publicly available patent data.)
